Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M Davis

Showing results (21-30 of 505) with videos related to

Pageof 51
Sort By:
Schizophrenia Bulletin|May 10, 2022
Choosing an Optimal Antipsychotic Dose for Relapse PreventionJohn M Davis, Hua Jin
The Lancet. Psychiatry|June 7, 2016
Second-generation antipsychotics and quality of life in schizophreniaStefan Leucht, John M Davis
The British Journal of Psychiatry : the Journal of Mental Science|September 3, 2017
Do antipsychotic drugs lose their efficacy for relapse prevention over time?Stefan Leucht, John M Davis
BMC Medicine|July 2, 2008
Commentary on strategies for switching antipsychoticsJohn M Davis, Stefan Leucht
European Psychiatry : the Journal of the Association of European Psychiatrists|January 12, 2005
Old versus new: weighing the evidence between the first- and second-generation antipsychoticsJohn M Davis, Nancy Chen
European Archives of Psychiatry and Clinical Neuroscience|January 17, 2022
Which first-generation antipsychotics should be "repurposed" for the treatment of schizophreniaStefan Leucht, John M Davis
Psychiatric Services (Washington, D.C.)|December 3, 2009
Commentary: real-time computerized support systemsJohn M Davis, Daniel J Luchins
Current Psychiatry Reports|December 2, 2005
Diagnosis and treatment of depression in patients with mental retardationDavid S Janowsky, John M Davis
Prostaglandins, Leukotrienes, and Essential Fatty Acids|July 22, 2009
Considerations regarding neuropsychiatric nutritional requirements for intakes of omega-3 highly unsaturated fatty acidsJoseph R Hibbeln, John M Davis
Current Rheumatology Reports|March 1, 2021
Etiologies of Rheumatoid Arthritis: Update on Mucosal, Genetic, and Cellular PathogenesisVanessa L Kronzer, John M Davis
Pageof 51

Showing results (21-30 of 505) with videos related to

Sort By:
Pageof 51
Schizophrenia Bulletin|May 10, 2022
Choosing an Optimal Antipsychotic Dose for Relapse PreventionJohn M Davis, Hua Jin
The Lancet. Psychiatry|June 7, 2016
Second-generation antipsychotics and quality of life in schizophreniaStefan Leucht, John M Davis
The British Journal of Psychiatry : the Journal of Mental Science|September 3, 2017
Do antipsychotic drugs lose their efficacy for relapse prevention over time?Stefan Leucht, John M Davis
BMC Medicine|July 2, 2008
Commentary on strategies for switching antipsychoticsJohn M Davis, Stefan Leucht
European Psychiatry : the Journal of the Association of European Psychiatrists|January 12, 2005
Old versus new: weighing the evidence between the first- and second-generation antipsychoticsJohn M Davis, Nancy Chen
European Archives of Psychiatry and Clinical Neuroscience|January 17, 2022
Which first-generation antipsychotics should be "repurposed" for the treatment of schizophreniaStefan Leucht, John M Davis
Psychiatric Services (Washington, D.C.)|December 3, 2009
Commentary: real-time computerized support systemsJohn M Davis, Daniel J Luchins
Current Psychiatry Reports|December 2, 2005
Diagnosis and treatment of depression in patients with mental retardationDavid S Janowsky, John M Davis
Prostaglandins, Leukotrienes, and Essential Fatty Acids|July 22, 2009
Considerations regarding neuropsychiatric nutritional requirements for intakes of omega-3 highly unsaturated fatty acidsJoseph R Hibbeln, John M Davis
Current Rheumatology Reports|March 1, 2021
Etiologies of Rheumatoid Arthritis: Update on Mucosal, Genetic, and Cellular PathogenesisVanessa L Kronzer, John M Davis
Pageof 51